News Centessa Pharmaceuticals plc

Equities

CNTA

US1523091007

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-06-05 pm EDT			5-day change	1st Jan Change
39.62 ^USD	-0.45%		-0.35%	+58.42%

May. 26	Eli Lilly to Acquire Three Vaccine Developers for Up to $3.83 Billion	MT
May. 20	Eli Lilly Buys Engage Biologics for Up to $202 Million	DJ

All News

Mentions Relevance

May. 11	Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA	BU
May. 05	Centessa Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 20	Wells Fargo Downgrades Centessa Pharmaceuticals ADR to Equal Weight From Overweight, Adjusts Price Target to $42 From $35	MT
Apr. 01	B. Riley Downgrades Centessa Pharmaceuticals to Neutral From Buy, Lifts Price Target to $45 From $42	MT
Apr. 01	Leerink Partners Downgrades Centessa Pharmaceuticals to Market Perform From Outperform, $36 Price Target	MT
Mar. 31	Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA	BU
Mar. 31	Centessa Pharmaceuticals plc Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Mar. 31	Are APLS, CNTA, BIRD Obtaining Fair Deals for their Shareholders?	PR
Mar. 31	Eli Lilly and Company entered into a definitive agreement to acquire Centessa Pharmaceuticals plc from a group of shareholders for $5.1 billion.	CI
Mar. 31	CNTA Stock Alert: Halper Sadeh LLC is Investigating Whether Centessa Pharmaceuticals plc is Obtaining a Fair Price for its Shareholders	BU
Mar. 31	Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders	PR
Mar. 30	Centessa Pharmaceuticals Insider Sold Shares Worth $1,237,382, According to a Recent SEC Filing	MT
Mar. 27	Centessa Pharmaceuticals Insider Sold Shares Worth $719,940, According to a Recent SEC Filing	MT
Mar. 19	Centessa Pharmaceuticals Insider Sold Shares Worth $2,109,180, According to a Recent SEC Filing	MT
Mar. 16	Centessa Pharmaceuticals Insider Sold Shares Worth $1,927,131, According to a Recent SEC Filing	MT
Mar. 16	Centessa Pharmaceuticals Insider Sold Shares Worth $3,150,673, According to a Recent SEC Filing	MT
Feb. 12	Centessa Pharmaceuticals : February 2026 Corporate Overview (597223)	PU
Feb. 04	Centessa Pharmaceuticals Insider Sold Shares Worth $1,004,918, According to a Recent SEC Filing	MT
Feb. 03	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences	GL
Feb. 03	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences	AQ
Jan. 15	Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting	AQ
Jan. 14	Centessa Pharmaceuticals : CNT-9982, an orexin receptor 2 agonist, enhances wakefulness in marmosets, and in the Wistar Kyoto rat model of major depressive disorder, normalizes the arousal state phenotype and alleviates behavioral despair (743a9b)	PU
Jan. 14	Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting	GL
Jan. 10	Certain Options of Centessa Pharmaceuticals plc are subject to a Lock-Up Agreement Ending on 11-JAN-2026.	CI
Jan. 10	Certain Restricted Share Units of Centessa Pharmaceuticals plc are subject to a Lock-Up Agreement Ending on 11-JAN-2026.	CI